^
Association details:
| Biomarker: | EGFR exon 2-7 deletion + EGFR amplification |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation
Published date:
09/09/2021
Excerpt:
All patients received osimertinib/bevacizumab as a second-line intervention with a median progression-free survival (PFS) of 5.1 months (95% CI 2.8-7.3) and overall survival of 9.0 months (95% CI 3.9-14.0). The PFS6 was 46.7%, and the overall response rate was 13.3%....While the osimertinib/bevacizumab combination was marginally effective in most GB patients with simultaneous EGFR amplification plus EGFRvIII mutation, a subgroup experienced a long-lasting meaningful benefit.
DOI:
10.1007/s11060-021-03834-3
